Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
Open Access
- 8 October 2022
- journal article
- editorial
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11954
Abstract
Current studies concerning myotonic dystrophy type 1 (DM1) are in the process of transitioning from molecular investigations to preclinical and clinical trialsKeywords
Funding Information
- National Institutes of Health (5RO1NS115662, 5RO1AR073379)
- CCHMC (5RO1NS115662, 5RO1AR073379)
This publication has 20 references indexed in Scilit:
- Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1International Journal of Molecular Sciences, 2019
- Recovery in the Myogenic Program of Congenital Myotonic Dystrophy Myoblasts after Excision of the Expanded (CTG)n RepeatInternational Journal of Molecular Sciences, 2019
- MicroRNA-Based Therapeutic Perspectives in Myotonic DystrophyInternational Journal of Molecular Sciences, 2019
- Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohortNeurology, 2019
- Mitigating RNA Toxicity in Myotonic Dystrophy using Small MoleculesInternational Journal of Molecular Sciences, 2019
- CRISPR/Cas Applications in Myotonic Dystrophy: Expanding OpportunitiesInternational Journal of Molecular Sciences, 2019
- Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic DystrophyInternational Journal of Molecular Sciences, 2019
- Disease-associated repeat instability and mismatch repairDNA Repair, 2016
- Myotonic DystrophyNeurologic Clinics, 2014
- Myotonic Dystrophy in Transgenic Mice Expressing an Expanded CUG RepeatScience, 2000